Anti-FOLH1/ GCPII/ FGCP monoclonal antibody
Anti-FOLH1/ GCPII/ FGCP antibody for FACS & in-vivo assay
Go to GCPII/FOLH1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T97071-Ab-1/ GM-Tg-hg-T97071-Ab-2 | Anti-Human GCPII/FOLH1 monoclonal antibody | Human |
GM-Tg-rg-T97071-Ab-1/ GM-Tg-rg-T97071-Ab-2 | Anti-Rat GCPII/FOLH1 monoclonal antibody | Rat |
GM-Tg-mg-T97071-Ab-1/ GM-Tg-mg-T97071-Ab-2 | Anti-Mouse GCPII/FOLH1 monoclonal antibody | Mouse |
GM-Tg-cynog-T97071-Ab-1/ GM-Tg-cynog-T97071-Ab-2 | Anti-Cynomolgus/ Rhesus macaque GCPII/FOLH1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T97071-Ab-1/ GM-Tg-felg-T97071-Ab-2 | Anti-Feline GCPII/FOLH1 monoclonal antibody | Feline |
GM-Tg-cang-T97071-Ab-1/ GM-Tg-cang-T97071-Ab-2 | Anti-Canine GCPII/FOLH1 monoclonal antibody | Canine |
GM-Tg-bovg-T97071-Ab-1/ GM-Tg-bovg-T97071-Ab-2 | Anti-Bovine GCPII/FOLH1 monoclonal antibody | Bovine |
GM-Tg-equg-T97071-Ab-1/ GM-Tg-equg-T97071-Ab-2 | Anti-Equine GCPII/FOLH1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T97071-Ab-1/ GM-Tg-hg-T97071-Ab-2; GM-Tg-rg-T97071-Ab-1/ GM-Tg-rg-T97071-Ab-2; GM-Tg-mg-T97071-Ab-1/ GM-Tg-mg-T97071-Ab-2; GM-Tg-cynog-T97071-Ab-1/ GM-Tg-cynog-T97071-Ab-2; GM-Tg-felg-T97071-Ab-1/ GM-Tg-felg-T97071-Ab-2; GM-Tg-cang-T97071-Ab-1/ GM-Tg-cang-T97071-Ab-2; GM-Tg-bovg-T97071-Ab-1/ GM-Tg-bovg-T97071-Ab-2; GM-Tg-equg-T97071-Ab-1/ GM-Tg-equg-T97071-Ab-2 |
Products Name | Anti-GCPII/FOLH1 monoclonal antibody |
Format | mab |
Target Name | GCPII |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-GCPII benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Target information
Target ID | GM-T97071 |
Target Name | GCPII |
Gene ID | 2346,53320,85309 |
Gene Symbol and Synonyms | FGCP,FOLH,FOLH1,GCP2,GCPII,mGCP,mopsm,Naalad,NAALAD1,PSM,PSMA |
Uniprot Accession | Q04609,P70627 |
Uniprot Entry Name | FOLH1_HUMAN,FOLH1_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target, INN Index |
Disease | Prostate Cancer |
Gene Ensembl | ENSG00000086205 |
Target Classification | Checkpoint-Immuno Oncology |
The target: GCPII, gene name: FOLH1, also named as FGCP, FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA, mGCP. This gene encodes a type II transmembrane glycoprotein belonging to the M28 peptidase family. The protein acts as a glutamate carboxypeptidase on different alternative substrates, including the nutrient folate and the neuropeptide N-acetyl-l-aspartyl-l-glutamate and is expressed in a number of tissues such as prostate, central and peripheral nervous system and kidney. A mutation in this gene may be associated with impaired intestinal absorption of dietary folates, resulting in low blood folate levels and consequent hyperhomocysteinemia. Expression of this protein in the brain may be involved in a number of pathological conditions associated with glutamate excitotoxicity. In the prostate the protein is up-regulated in cancerous cells and is used as an effective diagnostic and prognostic indicator of prostate cancer. This gene likely arose from a duplication event of a nearby chromosomal region. Alternative splicing gives rise to multiple transcript variants encoding several different isoforms. [provided by RefSeq, Jul 2010].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.